Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HSV-Tk engineered donor lymphocytes
- Development stage
- Phase 2
- Lead developer
- AGC Biologics
- Modality
- Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Donor lymphocytes engineered to express the herpes simplex virus thymidine kinase (HSV-TK) gene are used as a form of adoptive cellular immunotherapy, particularly in the context of allogeneic hematopoietic stem cell transplantation (HSCT). The HSV-TK serves as a suicide gene, making transduced lymphocytes selectively sensitive to ganciclovir, which can be administered to eliminate these cells in the event of graft-versus-host disease (GvHD). This approach aims to enhance graft-versus-leukemia (GvL) effects and immune reconstitution after transplantation, while providing an on-demand mechanism to control severe alloreactivity and GvHD. These engineered cells have been investigated primarily for preventing relapse and improving immune reconstitution in patients with high-risk hematologic malignancies following haploidentical stem cell transplantation. The therapy is under advanced clinical evaluation and is not a conventional pharmaceutical product, but an individualized cell therapy manufactured for each patient[1][2][3][4].
- Brand names
- Zalmoxis
- Other names
- HSV-TK suicide gene-modified lymphocytesHSV-TK-transduced donor lymphocytesHSV-TK engineered lymphocytesTK-cells
02
Targets
HSV-TK (Herpes simplex virus type 1 thymidine kinase (HSV1-TK))
Beyond the preview
Go deeper on HSV-Tk engineered donor lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HSV-Tk engineered donor lymphocytes.